The Center for Biosimilars (CB) interviewed Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, and editorial board member of The Center for Biosimilars, on where the field stands today.
CB: What would be an ideal way to expand familiarity with biosimilars within the medical healthcare community?
Fuhr: Educational programs are the best way and this includes such entities as the FDA, pharmaceutical companies, and payers to educate physicians and patients.
CB: How can the oncology community in particular benefit from extended knowledge of biosimilars and, conversely, benefit the biosimilar industry?
Fuhr: Oncology drugs are some of the highest priced drugs. Biosimilars can decrease the price of these drugs, thus increasing access and improving the quality of life of more patients.
CB: Do you believe that biosimilar treatment options will make treatment more affordable?
Fuhr: Yes. Competition will lead to lower prices and we have seen this in the European Union.
CB: What would be the best-case scenario for biosimilar incorporation into mainstream medicine from a healthcare policy/cost perspective?
Fuhr: As patents expire and more biosimilars enter [the market], prices will decrease. It will take a while for the market to fully develop.
CB: What, in your opinion, is the greatest benefit represented by biosimilar uptake?
Fuhr: Lower prices and greater access, which will benefit consumers and help decrease prices in the healthcare market. Also, it will result in innovators’ attempting to find benefits on new drugs as profits on old drugs decline. Biosimilars will thus benefit society.
CB: Do you recognize the need for educating healthcare professionals and patients on biosimilars?
Fuhr: Many patients and physicians are unaware of what biosimilars are and the process that they must go through to achieve FDA approval. People are not going to purchase or prescribe something which they do not understand.
CB: Would biosimilars raise challenges with formulary management for health plans and for clinical pharmacies?
Fuhr: Any time a new alternative comes to market, formulary management and clinical pharmacies must make a decision on the circumstances under which they will adopt the alternative. So, they must decide on the quality and price of the product to determine not only if it will go onto the formulary but also on what tier in terms of health plans.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces
November 13th 2023At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.